Chugai has licensed marketing and development rights for CSG452 to Roche in January 2007 as a treatment for type II diabetes.
Roche’s decision was backed by the priority review of its development pipeline which enforced the company to return back the rights of CSG452.
Chugai will seek for other partner regarding overseas development.
Chugai intends to submit regulatory filing for the compound in 2013.